A carregar...

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeuti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Case Rep
Main Authors: Alderuccio, Juan Pablo, Desai, Amrita, Yepes, Monica M., Chapman, Jennifer R., Vega, Francisco, Lossos, Izidore S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://ncbi.nlm.nih.gov/pubmed/29636930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!